Tata Elxsi's shares dropped 6% following the announcement of its Q1 results, which revealed weaker-than-expected performance. Analysts from Motilal Oswal and Choice Institutional Equities have downgraded the stock, citing concerns over growth in key segments and margin pressures.
The company's profit before tax (PBT) for the quarter stood at Rs. 232.5 crore, marking an 18.4% increase from the previous year, with a PBT margin of 21.9%. Despite a strong operating performance with EBITDA rising 15.7% year-on-year to Rs. 216 crore, the EBITDA margin was 21.2%, and the net profit margin was 16.1%.
Motilal Oswal maintained its Sell rating on Tata Elxsi, setting a target price of Rs. 3,100, indicating a potential downside of around 16% from current levels. The brokerage highlighted that the company's June quarter performance did not significantly alter its broader growth outlook, with revenue growing 1.3% quarter-on-quarter in constant currency, largely driven by the Media & Communications segment. However, the Transportation business, which accounts for approximately 55% of revenue, and the Healthcare segment continued to show weakness.
“The company's June quarter performance does little to alter its broader growth outlook.”
Motilal Oswal
Choice Institutional Equities also downgraded Tata Elxsi to Sell, reducing its target price to Rs. 3,150 from Rs. 3,650. The brokerage cited weaker-than-expected Q1FY27 performance, with margins impacted by higher project costs and ongoing strategic investments, despite healthy growth in the Transportation and Media & Communications segments.
Tata Elxsi's management stated that its Healthcare and Life Sciences business grew 1.7% quarter-on-quarter, despite a subdued demand environment. The company is investing in AI-first, design-led engineering approaches and has launched new platforms like ViTEL and AnaTEL to enhance its offerings in the medtech and healthcare industry.
Background
Analysts are concerned about Tata Elxsi's growth prospects, particularly in the European automotive market, where client spending remains cautious. The company's ongoing investments in AI capabilities and strategic partnerships are expected to improve long-term growth prospects, but margins may remain under pressure in the near term.
Looking ahead, Tata Elxsi aims to maintain high single-digit revenue growth in FY27, supported by a robust large-deal pipeline and anticipated recovery in the Healthcare business. However, analysts remain cautious, citing risks such as continued weakness in key markets and delays in order conversions.
